Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted optimization of induction and consolidation chemotherapy for acute myeloid leukemia
ChiCTR-TRC-10001202Phase 3Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2010
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cytarabine, daunorubicin and homoharringtonine in acute myeloid leukemia (AML) (4 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Complete remission rate by risk group, Disease-free survival by risk group and 1 more. Started Sep 2010; status: completed.
02
Drugs
cytarabinedaunorubicinhomoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-TRC-10001202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001202.